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Abstract   
Background   
This is an update of a Cochrane review first published in 2003, and previously updated in 2009 (no change 
in conclusions). Cervical dystonia is the most common form of focal dystonia and is a disabling disorder 
characterized by painful involuntary head posturing. Botulinum toxin type A (BtA) is usually considered 
the first line therapy for this condition, although botulinum toxin type B (BtB) is an alternative option, 
with no compelling theoretical reason as to why it might not be as, or even more effective, than BtA. 
Objectives   
To compare the efficacy, safety, and tolerability of botulinum toxin type A versus botulinum toxin type B 
in cervical dystonia. 
Search methods   
We identified studies for inclusion in the review using the Cochrane Movement Disorders Group trials 
register, the Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, reference lists of 
articles and conference proceedings, last run in October 2015. Search was unrestricted by language. 
Selection criteria   
Double-blind, parallel, randomised, placebo-controlled trials (RCTs) of BtA versus BtB in adult patients 
with cervical dystonia. 
Data collection and analysis   
Two independent authors assessed records, selected included studies, extracted data using a paper pro 
forma and evaluated the risk of bias. Disagreements were solved by consensus or by a third author. We 
performed one meta-analysis for the comparison BtA versus BtB. We used random-effects models in the 
presence of considerable heterogeneity and fixed-effect models when there was no heterogeneity. We 
performed no subgroup analyses. The primary efficacy outcome was overall improvement on any validated 
symptomatic rating scale. The primary safety outcome was the proportion of participants with any adverse 
event. 
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Main results   
Three RCTs of low-to-moderate overall methodological quality including 270 participants with cervical 
dystonia were included. Two studies exclusively enrolled patients known to have a positive response to 
BtA treatment, therefore including an enriched population with higher probability of benefit from BtA 
treatment. None of the trials were independently funded. All RCTs evaluated the effect of a single Bt 
treatment session using doses between 100 and 250U of BtA and 5000 to 10000U of BtB. We found no 
difference between the two types of botulinum toxin in terms of overall efficacy and safety, as assessed by 
the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) and the number of adverse events, 
respectively. However, when compared to BtA, treatment with BtB was associated with an improvement 
of 0.99 points (95% CI: 0.12 to 1.85; I2=0%) on the TWSTRS pain sub-scale at weeks 2-4 after injection, 
as well as with an increased risk of treatment-related dysphagia with a risk ratio (RR) of 0.49, favouring the 
BtA group (95% CI: 0.32 to 0.75, I2=27%) and sore throat/dry mouth, with a RR of 0.42 favouring the 
BtA group (95% CI: 0.31 to 0.57, I2=77%). The two types of botulinum toxin were otherwise shown to be 
clinically non-distinguishable in all the remaining outcomes. 
Authors' conclusions   
A single treatment session of BtA and a single treatment session of BtB are equally effective and well 
tolerated in the treatment of adults with certain types of cervical dystonia. Treatment with BtB causes a 
greater decrease disease-associated pain whilst also increasing the rate of dysphagia and sore throat/dry 
mouth when compared to treatment with BtA. Overall, there is no clinical evidence to support or not 
support the preferential use of one form of botulinum toxin over another. There is no evidence from 
RCTs neither regarding comparative development of secondary non-responsiveness to botulinum toxin 
nor regarding quality of life domains with either treatment. 
 
Resumo em Língua Portuguesa 
A distonia cervical compreende uma patologia neurológica pouco frequente com impacto negativo na 
qualidade de vida dos doentes. O tratamento de primeira linha é com efetuado com recuro a injecções 
intramusculares de toxina botulínica, que está disponível comercialmente em dois tipos: a toxina botulínica 
tipo A e a toxina botulínica tipo B. Esta revisão sistemática Cochrane visa comparar estes dois compostos 
em relação à sua eficácia e segurança no tratamento da distonia cervical. Após um processo de pesquisa 
sistemática para ensaios aleatorizados sobre o tema, extração de dados e combinação dos mesmos com 
recurso a técnicas de combinação por meta-análise, demonstrou-se que não existem diferenças nos perfis 
de eficácia e segurança entre ambas as formulações de toxina botulínica, com as exepções de uma subescala 
de doença (avaliador dor) e a proporção de doentes com efeitos adversos específicos.  
 
Plain language summary   
A comparison of botulinum toxin type A versus botulinum toxin type B for 
involuntary positioning of the head, or cervical dystonia 
  
Undesired, uncontrollable, and often painful, placement of the head, a disease called cervical dystonia or 
spasmodic torticollis, is a relatively uncommon condition (affecting 57 to 280 per million) that can be very 
disabling and can compromise quality of life. Most times the cause is unknown and no cure exists. As this 
is typically a chronic disease it requires long-term treatment. 
Botulinum toxin is a natural powerful chemical produced by a bacterium called Clostridium botulinum, that 
can cause severe paralysis in animals and humans. It can also be used to treat many conditions, in particular 
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those with involuntary muscle contractions, such as cervical dystonia, by delivering intra-muscular 
botulinum toxin injections. There are different types of Bt, not all available for therapeutic purposes. 
Botulinum toxin type A (BtA) is normally the first-used treatment in cervical dystonia, but botulinum toxin 
type B (BtB) is considered an alternative option. 
This update of a previous Cochrane review aimed to assess the effectiveness (reduction in severity, 
disability and pain) and safety of BtA compared with BtB in cervical dystonia. 
We performed a literature search in October 2015 for studies that compared BtA with BtB in patients with 
cervical dystonia. 
We found three studies comparing a single treatment sessions of both BtA and BtB in 270 patients. 
There was low-to-moderate quality evidence that there is no difference between BtA and BtB. BtB-treated 
patients, however, have slightly less pain due to their condition and at the same time are at an increased 
risk of swallowing difficulties and feel dry mouth/sore throat. 
Further studies are needed to establish the long-term comparative benefit of both types of treatment, 
including its impact on quality of life, and to find which, if any, treatment is associated with more patients 
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Summary of findings 
Botulinum toxin type A versus Bptulinum toxin type B for Cervical Dystonia 
Patient or population: Adults with Cervical Dystonia  
Setting: Hospital-based, movement disorders clinics 
Intervention: Botulinum toxin type A 
Comparison: Botulinum toxin type B 


















baseline to week 4  






baseline to week 4 
was 0  
The mean overall 
Cervical Dystonia 
improvement as 
assessed with validated 
scales: change from 
baseline to week 4 in the 
intervention group was 
1.44 fewer (3.58 fewer to 
0.7 more)  
-  231 







baseline to week 2-
4 as assessed with 
validated scales  
The mean cervical 
Dystonia associated 
Pain: change from 
baseline to week 2-4 
as assessed with 
validated scales was 
0  
The mean cervical 
Dystonia associated 
Pain: change from 
baseline to week 2-4 as 
assessed with validated 
scales in the intervention 
group was 0.99 fewer 
(1.85 fewer to 0.12 
fewer)  
-  251 






as assessed by the 
patient at week 4  
The mean subjective 
change as assessed 
by the patient at 
week 4 was 0  
The mean subjective 
change as assessed by 
the patient at week 4 in 
the intervention group 
was 0.2 more (0.17 
fewer to 0.57 more)  
-  138 







adverse events  









661 per 1000  
476 per 1000 
(337 to 661)  










346 per 1000  
170 per 1000 
(111 to 260)  
Sore Throat/Dry 
Mouth  









612 per 1000  
257 per 1000 
(190 to 349)  
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and 
the relative effect of the intervention (and its 95% CI).  
 
CI: Confidence interval; MD: Mean difference; RR: Risk ratio  
GRADE Working Group grades of evidence 
High quality: We are very confident that the true effect lies close to that of the estimate of the effect 
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the 
effect, but there is a possibility that it is substantially different 
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the 
effect 
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the 
estimate of effect  
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Background   
This review is an update of a previously 
published review in the Cochrane Database of 
Systematic Reviews 2003, Issue 3 (Costa 2003), 
evaluating the efficacy and safety of botulinum 
toxin type A (BtA) versus botulinum toxin type 
B (BtB) in the treatment of cervical dystonia. 
Description of the condition   
Dystonia is the third most common movement 
disorder, after Parkinson’s disease and essential 
tremor, with an overall prevalence of 164 per 
million (Steeves 2012). Dystonia syndromes are 
a group of disabling, painful disorders 
characterized by involuntary sustained or 
intermittent muscle contractions causing 
abnormal, often repetitive, movements or 
postures of the face, neck, trunk or limbs 
(Albanese 2013). Dystonic movements are 
typically patterned or twisting, and are often 
initiated or worsened by voluntary action 
(Albanese 2013). These neurological disorders 
can be classified based on topographic 
distribution, including focal dystonia (one body 
region, e.g. cervical dystonia and 
blepharospasm), segmental dystonia (two or 
more adjacent regions, e.g. hemifacial spasm), 
multifocal dystonia (two or more nonadjacent 
regions), hemidystonia (ipsilateral regions) and 
generalized dystonia (trunk and two or more 
other regions) (Albanese 2013; Tarsy 2006). 
Focal dystonia is a highly disabling movement 
disorder, with serious functional and social 
impairment. At the average age of 40 years, 
almost half of the patients quit working or retire 
early due to dystonia, and 10 years later, only 
25% of patients are working compared to 62% 
of the general population (Zoons 2012). 
Moreover, health-related quality of life is 
significantly diminished, mainly attributable to 
depression and anxiety, with scores comparable 
to patients with multiple sclerosis, Parkinson’s 
disease or stroke (Zoons 2012). 
Cervical dystonia, also called spasmodic 
torticollis, is the most common form of adult-
onset focal dystonia, with estimates from 
population studies ranging from 57 per million 
in Europe (ESDE 2000) to as high as 280 per 
million in the USA (Jankovic 2006). It typically 
has its onset in the fifth decade (Albanese 2013), 
and affects more women than men (Defazio 
2013). This condition is characterized by 
abnormal movements of head, neck, and 
shoulder, resulting in posturing of the head away 
from its normal central position (Foltz 1959). It 
may present predominantly with sustained 
abnormal posture, spasm, jerks, tremor, or a 
combination of these features. Neck and/or 
shoulder pain occur in more than 70% of 
patients (Tarsy 2006; Chan 1991). 
Cervical dystonia can be classified according to 
the dominant head position, with the most 
common type involving horizontal turning, the 
so-called rotatory (or simple) torticollis 
(Albanese 2013; Chan 1991). Other common 
patterns include laterocollis (tilt to one side), 
retrocollis (tilt upwards resulting in neck 
extension) and anterocollis (tilt downwards 
resulting in neck flexion). Complex torticollis, a 
combination of these abnormal patterns, is yet 
very frequent to find in clinical practice. 
The etiology of most forms of dystonia is still 
not fully understood, with the exception of 
early-onset dystonia, for which an hereditary 
etiology is common (Balint 2015). In most cases 
of focal adult-onset dystonia, such as cervical 
dystonia, the pathophysiology is generally 
considered to result from inhibition of the 
central nervous system (CNS) at multiple levels 
(Hallett 1998) resulting in abnormal 
sensorimotor integration. Cervical dystonia can 
also be secondary to brain injury, infections of 
the CNS, drugs (such as levodopa or 
antipsychotics), toxics, vascular or neoplastic 
disorders and may also be psychogenic (i.e., 
functional) (Albanese 2013). Although most 
cases of cervical dystonia are currently classified 
as idiopathic, it should be observed that some 
may came to be reclassified as inherited, since 
new gene discoveries are under investigation 
(Albanese 2013; Balint 2015). 
The natural course of cervical dystonia remains 
unclear. It usually develops gradually and 
deteriorates over the initial years. The clinical 
presentation is seldom progressive to 
generalized dystonia, although it often extends 
to contiguous body regions. For most patients, 
cervical dystonia is a life-long disorder, with only 
about 10% undergoing spontaneous remissions 
(Jahanshani 1990). 
To date, no curative or disease-modifying 
treatments are available for cervical dystonia. 
Description of the intervention   
Botulinum toxin (Bt) is a powerful biological 
toxin produced by Clostridium botulinum. The 
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active form of botulinum toxin is a di-chain 
polypeptide composed of two chains: a heavy 
chain (100 kDa) and a light chain (50 kDa), and 
by associating with certain auxiliary proteins 
(hemagglutinins and non-hemagglutinins), the 
toxin forms a complex of variable size (Simpson 
2004). The nontoxic proteins aid in the 
formation of neutralizing antibodies, though 
beyond this their role is unclear (Frevert 2010). 
Bt binds to peripheral cholinergic nerve 
terminals of the neuromuscular junction as well 
as sympathetic ganglionic, parasympathetic 
ganglionic and postganglionic terminals 
(Simpson 2004). Bt, after binding to an acceptor 
protein, is endocytosed at the presynaptic 
membrane of acetylcholine nerve terminals 
(Pellizzari 1999). By action of the N-terminal on 
the heavy-chain, a pore is formed on the 
endocytic membrane, which permits the release 
of the light-chain into the cytosol. This light 
chain, which is a zinc protease, performs the 
key-action of the botulinum toxin, by cleaving 
soluble N-ethylmaleimidesensitive factor 
attachment receptor proteins (SNARE proteins) 
(Pellizzari 1999). 
SNAREs are docking proteins for acetylcholine 
vesicles that allow for the release of 
acetylcholine into the synaptic cleft (Pellizzari 
1999). As the fusion of the vesicle membranes 
becomes inhibited, there is a temporary 
blockade of acetylcholine release at cholinergic 
synapses, causing a local chemodenervation. 
Temporary synapses are consequently formed 
via the process of axonal sprouting (Duchen 
1971; Holland 1981; Juzans 1996). 
There are seven immunologically distinct 
botulinum toxin serotypes (labelled A to G). 
These different Bt serotypes cleave specific 
SNARE proteins. Serotype A cleave SNARE 
protein SNAP 25 located on the inner 
membrane, and serotype B targets synaptobrevin 
located on the vesicular membrane (Pellizzari 
1999). 
Botulinum toxin is injected into the muscles 
involved in dystonia, with or without guidance 
by either electromyography (EMG) or 
ultrasound. As a general rule, the number of 
muscles injected and the number of injection 
sites per muscle are tailored to the severity of the 
case in question and the mass of the muscle, 
respectively. Within roughly three months after 
injection of botulinum toxin into skeletal 
muscle, the nerve terminal resumes exocytosis, 
and the muscle returns to its baseline clinical 
function, showing a wearing off response from 
the Bt injection (Jankovic 2004). Eventually, the 
muscle paralysis subsides, and this is associated 
with the formation of new sprouts capable of 
neurotransmission. Over time, synaptic activity 
resumes in the original nerve terminals, leading 
to sprout regression (de Paiva 1999). 
Currently there are two commercially available 
botulinum toxin serotypes (BtA and BtB). The 
following products are commonly available 
(three BtA and one BtB): onabotulinumtoxinA 
(Botox®, Allergan Inc., Irvine, CA, USA), 
abobotulinumtoxinA 
(Dysport®/Reloxin®/Azzalure®, Ipsen 
Pharma, Boulogne Billancourt, France), 
incobotulinumtoxinA (Xeomin®/Bocoture® 
Merz GmbH, Frankfurt, Germany), and 
rimabotulinumtoxinB (Myobloc®/Neurobloc®, 
Solstice Neurosciences Inc., Louisville, KY, 
USA). Other BtA formulations are available in 
more restricted markets and are yet to receive a 
generic name: Prosigne®/Lantox® (Lanzhou 
Institute of Biological Products, China), 
PurTox® (Mentor Worldwide LLC, Santa 
Barbara, CA, USA), and Neuronox® (Medy-Tox 
Inc, South Korea)(Walker 2014). 
How the intervention might 
work   
The therapeutic potential of all Bt serotypes 
derives from its ability to inhibit the release of 
acetylcholine from the presynaptic nerve 
terminal into the synaptic cleft, causing local 
chemodenervation (Jankovic 2004). In addition 
to this, recent research has also suggested that Bt 
is active at the level multiple levels, namely 
sensory nerve terminals, and muscle spindles, 
which leads to a reduction in sensory input and 
fewer muscle contractions (Matak 2014; Filippi 
1993; Rosales 1996; Rosales 2010). 
It has also been suggested that cortical 
reorganization may result from changes in the 
spinal cord, brainstem and central nervous 
pathways (Palomar 2012). Animal research has 
shown the presence of supra-therapeutic levels 
of Bt by way of retrograde axonal transport and 
penetration of the central nervous system 
(Boroff 1975; Antonucci 2008). However, Bt has 
not been shown to penetrate the blood-brain 
barrier in humans. 
Until recently, SNARE proteins were considered 
the only target-molecules of Bt. Thus, it was 
widely accepted that the therapeutic and toxic 
actions of Bt were exclusively mediated by 
SNARE cleavage preventing the release of 
synaptic neurotransmitters. However, recent 
studies have suggested that a number of Bt 
actions night not be mediated by SNARE 
cleavage, specifically regarding neuroexocytosis, 
cell cycle and apoptosis, neuritogenesis and gene 
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expression (Matak 2015). The existence of 
unknown Bt molecular targets and modulation 
of unknown signalling pathways is a possibility 
that may prove to be pharmacologically relevant. 
Why it is important to do this 
review   
BtA is the toxin serotype that has been most 
intensively studied and approved for the 
treatment of the large number of focal dystonias. 
BtA is considered the first line therapy for 
cervical dystonia and has proven to be effective 
in the symptomatic management of this 
condition (Albanese 2013). However, not all 
patients have an adequate clinical response. 
Primary non-response to botulinum toxin is 
seen in cases where the first and subsequent 
treatment cycles do not elicit a response. Cases 
of secondary non-response, however, respond to 
initial treatment, but over the course of multiple 
treatment cycles, this effect wanes and is 
eventually lost. Secondary non-response is 
partially explained by the formation of 
neutralizing antibodies, though it is worth noting 
that there are cases of secondary non-responders 
without positive antibody titers (Hanna 1998; 
Lange 2009) as well as cases with positive titers 
but with an adequate sensitivity to Bt (Brin 2008; 
Müller 2009). An estimated 4-20% of patients 
develop neutralizing antibodies to the toxin 
(Brashear 2008; Fabbri 2015), and if secondary 
non-responsiveness occurs, it is partially related 
to the protein load, with higher protein load per 
dose generating higher antibody titers (Benecke 
2012; Frevert 2010). 
When clinical non-response occurs, other 
botulinum toxin serotypes are important 
treatment options for cervical dystonia (Cullis 
2000; Eleopra 1997; Greene 1993). At the 
present time, BtB is the only approved non-BtA 
formulation available for the treatment of 
cervical dystonia in the European Union and 
North America. 
Although different botulinum toxin subtypes 
have different molecular targets, to date we 
know of no evidence from systematic reviews or 
randomised controlled trials that presents 
conclusive evidence regarding the comparative 
effectiveness of BtA and BtB for treating 
cervical dystonia. 
A Cochrane systematic review previously 
assessed the efficacy and safety of BtA versus 
BtB in patients with cervical dystonia. This is the 
second update of that review having been 
previously updated in 2009, with no changes to 
conclusions. The original review concluded that 
it was not possible to make definitive 
comparisons between BtA and BtB for the 
treatment of cervical dystonia, having included 
zero trials. 
Since the release of the original review, three 
trials were published (Comella 2005; Pappert 
2008; Tintner 2005). Furthermore, Cochrane’s 
criteria for evaluating studies' risk of bias and 
evidence quality have evolved and been updated. 
Therefore, the authors consider it important to 
update this review. 
Objectives   
To compare the clinical efficacy and safety of 
botulinum toxin type A (BtA) versus botulinum 
toxin type B (BtB) in the treatment of adults 
with cervical dystonia. 
Methods   
Criteria for considering studies for 
this review   
Types of studies   
Randomised controlled trials (RCTs), blinded, 
single or multiple dose, parallel-designed, of any 
duration, assessing efficacy and/or safety of 
treatment with BtA versus BtB in patients with 
cervical dystonia were eligible for inclusion in 
this review. We excluded trials in which 
allocation was not adequately concealed. Non-
parallel study designs, namely cross-over trials 
among others, were excluded in this updated 
version of the review due to uncertainty whether 
this type of study design is appropriate to study 
patients with cervical dystonia, as well as 
methodological concerns with regards to 
detection and performance bias. 
Types of participants   
Participants of an adults age (≥ 18 years of age), 
in any setting with a clinical diagnosis, made by 
any physician, specialist or otherwise, of 
idiopathic cervical dystonia. Trials enrolling 
participants with any form of cervical dystonia, 
and additional or more widespread dystonias, 
were allowed for inclusion. Participants could 
have had prior exposure to BtA or BtB, and 
could be taking any concomitant medications if 
on stable regimens. 
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There were no restrictions regarding the number 
of participants recruited to trials, or the number 
of recruitment centres. 
Types of interventions   
Intramuscular injections of BtA compared to 
BtB. All administration schedules and injection 
techniques, performed with or without guidance 
by either EMG or echography, were included. 
Types of outcome measures   
Primary outcomes   
The primary efficacy outcome was: 
Overall improvement on any validated 
symptomatic rating scale, such as Cervical 
Dystonia Severity Scale (CDSS), Tsui scale, and 
Toronto Western Spasmodic Torticollis Rating 
Scale (TWSTRS). 
The primary safety outcome was: 
Proportion of participants with any adverse 
event. 
Secondary outcomes   
The secondary outcomes were: 
1. Change in subjective evaluation of clinical 
status evaluated both by patients and clinicians, 
as assessed with validated assessment tools such 
as Patient Subjective Assessment of Change, 
Patient Global Assessment of Improvement, 
Patient Evaluation of Global Response (PEGR), 
Patient and Physician Global Assessment of 
Change, Investigator Global Assessment of 
Efficacy (IGAE), and Physician Global 
Assessment of Change (PGAC), and Visual 
analogue scale (VAS) for symptom severity. 
2. Changes in pain scores, as assessed with 
validated assessment tools such as Patient 
Assessment of Pain, TWSTRS-pain sub-scale 
score, and VAS Pain score. 
3. Changes in quality of life assessments, as 
assessed with validated assessment tools such as 
Short Form 36 (SF-36) Quality-of-Life 
questionnaire. 
4. Numbers of participants with specific adverse 
events, such as dysphagia, sore throat, and local 
injection-site pain. 
5. Duration of effect, assessed by the number of 
days until need for reinjection or effect waning. 
Search methods for identification 
of studies   
For this update, the search strategy was 
expanded to capture all the search terms for BtA 
and BtB formulations that are currently 
available. The search strategy was designed to 
include other botulinum toxin formulations and 
other dystonic disorders that are also under 
current revision by our group. 
Electronic searches   
The final search for the original version of this 
review was run in June 2003, based on the 
search strategy developed for the Movement 
Disorders Group to identify all papers from 
1977, the first year botulinum toxin was used 
therapeutically in any condition. The subsequent 
search for this update was run for the last time 
in October 2015. 
For the identification of studies considered for 
inclusion in this review, detailed search strategies 
were developed for each database searched. 
Please see Appendix 1 for the MEDLINE 
search strategy, Appendix 2 for the EMBASE 
strategy, and Appendix 3 for the CENTRAL 
strategy. 
Non-English papers were equally assessed, 
translated as necessary and evaluated for 
inclusion. 
Databases searched: 
(1) Cochrane Movement Disorders Group trials 
register (June 2003); 
(2) Cochrane Central Register of Controlled 
Trials (CENTRAL) (The Cochrane Library 
2015, Issue 11); 
(3) MEDLINE (1977 to October 2015); 
(4) EMBASE (1977 to October 2015). 
Searching other resources   
The search strategy also included: 
(1) Search through reference lists of located 
trials and review articles concerning botulinum 
toxin; 
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(2) Handsearch of abstracts of international 
congresses relevant in the fields of movement 
disorders and botulinum toxins, i.e. American 
Academy of Neurology, Movement Disorders 
Society, International Association of 
Parkinsonism and Related Disorders, and 
International Neurotoxin Association (1985 to 
October 2015); 
(3) Personal communication with other 
researchers in the field; 
(4) Contact with drug manufacturers; 
(5) Whenever necessary, authors of published 
trials were contacted for further information and 
unpublished data. 
Data collection and analysis   
Selection of studies   
Two review authors independently screened the 
studies identified by the search strategy, reading 
each of the titles and abstracts, excluding studies 
that were not applicable. If there was no 
abstract, we opted to retrieve the full text of the 
study in question. 
Two review authors then independently assessed 
the full-text articles to see if the studies fulfilled 
the inclusion criteria. Disagreements were 
resolved by discussion or, if necessary, 
consensus was reached with the participation of 
a third author. 
Data extraction and management   
Two authors independently extracted study data 
onto standardized forms, after which the forms 
were cross-checked for accuracy. Disagreements 
were resolved by discussion or, if necessary, 
arbitration by a third author. The following data 
was extracted from each study: 
1. Participants: inclusion and exclusion criteria, 
demographics and clinical baseline 
characteristics, number and reasons for 
withdrawals, exclusions and lost to follow-up, if 
any. 
2. Interventions: full description of intervention, 
duration of treatment period and follow-up, 
providers, and co-interventions, if any. 
3. Comparisons: number of randomised 
participants to each arm, compliance and 
dropouts, reasons for dropouts, and ability to 
perform an intention-to-treat analysis. 
4. Outcomes: definition of outcomes, use of 
validated measurement tools, time-point 
measurements, change from baseline or post-
interventional measures, and missing outcomes, 
if any. 
5. Study design: interventional, randomised, 
controlled, double-blind. 
Assessment of risk of bias in 
included studies   
The recommended Cochrane tool for assessing 
risk of bias was used in this review. Two new 
criteria were added, in addition to the six specific 
domains of this tool (i.e. random sequence 
generation, allocation concealment, blinding of 
participants and personnel, blinding of outcome 
assessment, incomplete outcome data, and 
selective reporting). One extra domain, 'enriched 
population', was created to evaluate bias 
originating from either: 1. Exclusive enrolment 
of known positive responders to BtA or 2. the 
exclusion of known poor responders to BtA. A 
second criteria, to assess the study source of 
funding, was added in the ‘other bias’ domain 
and identified as 'independent funding'. 
By excluding non-responders or preferentially 
including responders to BtA there is a possibility 
that these patients will respond more favourably 
to BtA than would a naive population. 
Whenever a study population consisted primarily 
of non-naive patients, this potential source of 
bias for subjective outcome assessment was 
taken into account. We also divided the domain 
'blinding of outcome assessment' into two 
categories: subjective and objective assessment. 
Two independent review authors performed 
critical assessments for each domain of the risk 
of bias tool. Disagreements were resolved by 
discussion and, if necessary, consensus was 
reached with the participation of a third author. 
Measures of treatment effect   
The improvement from baseline to weeks 3 to 6 
in disease symptoms was compared between 
BtA and BtB arms. Whenever possible, 
continuous outcomes were extracted. These data 
were then pooled from the studies, where 
adequate, and used for comparison. We opted to 
preferentially use mean differences. When 
studies investigating the same outcome used 
different validated rating scales, a standardized 
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mean difference (SMD) was calculated. For 
interpretation of effect sizes with SMDs, a rule 
of thumb was used to define absence of effect 
(SMD < 0.2), a small effect (SMD = 0.2 to 0.49), 
a moderate effect (SMD = 0.5 to 0.79), or a 
large effect (SMD ≥ 0.80) (Cohen 1988). If 
necessary for comparison, rating scales were 
dichotomized using each author's own criteria 
for improvement or no improvement. If these 
criteria were not described, 'improvement' was 
defined as any beneficial change from baseline, 
and 'no improvement' as lack of improvement 
or any deterioration from baseline. 
The proportion of participants with adverse 
events was compared between treatment arms, 
and further analysis was performed for the most 
frequent adverse events reported in trials. 
A meta-analysis was planned for the duration of 
effect of both botulinum toxin formulations 
(using time-to-event data). Where there were no 
data that could be combined and subjected to 
such analysis, we undertook a narrative approach 
to result synthesis. 
Unit of analysis issues   
Studies with multiples treatment groups: 
Whenever the included studies had multiple 
arms with different dosages of one (or two) of 
the botulinum toxins, all the groups were 
combined to create a single pair-wise 
comparison, using the RevMan5.3 Calculator. 
This avoided the duplication of the placebo 
group that would happen if multiple 
comparisons (e.g., dose1 versus BtX; dose2 
versus BtX) were included in the meta-analysis, 
as well as the loss of information if one dosage 
group was chosen in detriment of the others. 
The importance of dosage was later analysed in a 
subgroup analysis. 
Dealing with missing data   
Where insufficient data were presented in the 
study report to combine information into the 
meta-analysis, the mean value and standard 
deviation (SD) of the outcome measurements 
were pooled trough appropriate statistics, if 
available. 
The generic inverse variance method was used 
when an effect estimate and a valid measure of 
uncertainty (e.g. standard error (SE), 95% 
confidence interval (CI) or exact P value) were 
reported in the study. When two reported 
groups needed to be combined into a single 
group, a pooled standard deviation formula was 
used to obtain a valid approximation to the 
group standard deviation. 
When change from baseline SD was not 
reported or possible to extract, alternative 
methods for imputing SD were used. If a study 
in the same review using the same scale, degree 
of error and time period measurements was 
available, SD was appropriated from that study. 
Where not possible, a pooled SD formula was 
used instead, assuming a lower degree of 
accuracy. 
Assessment of heterogeneity   
Heterogeneity between trial results was tested 
using a standard chi-squared test and an I2 
statistic was performed for quantifying 
inconsistency across studies. When considerable 
heterogeneity was present (i.e. I2 > 50% or p < 
0.1), the possible causes of heterogeneity were 
explored by conducting subgroup analysis. 
Where heterogeneity could not readily be 
explained by the exploratory analyses performed, 
it was incorporated into a Random-Effects (RE) 
meta-analysis model. 
Assessment of reporting biases   
Publication bias was assessed through visual 
inspection of funnel plots asymmetry and Peters’ 
regression tests (Sterne 2001; Peters 2006), if 
more than 10 studies per outcome were available 
(Higgins 2011). 
Data synthesis   
Statistical analysis was performed with Review 
Manager version 5.3. 
Dichotomous data were preferentially reported 
in this review as risk ratios (RR) using a Mantel-
Haenszel fixed-effects (FE) model and 95% 
confidence intervals. If no risk estimate was 
available, the crude RR was derived from raw 
data. Continuous outcomes were reported as 
mean differences and 95% confidence intervals. 
The number of participants needed to treat for 
an additional beneficial outcome (NNTB) and 
for an additional harmful outcome (NNTH) 
were calculated from meta-analysis estimates 
rather than treating data as if it came from a 
single trial as the last approach is more prone to 
bias, especially when significant imbalances 
between groups within one or more trials in the 
meta-analysis exists (Altman 2002). However, 
caution is needed in interpreting these findings 
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since they may be misleading because of 
variation in the event rates in each trial, 
differences in the outcomes considered, effects 
of secular trends on disease risk, and differences 
in clinical setting (Smeeth 1999). 
Where data from the studies reports could not 
be combined into a meta-analysis, a narrative 
approach to result synthesis was included in the 
review text. 
Subgroup analysis and investigation 
of heterogeneity   
No a priori subgroups were defined for the 
current review. 
Results   
Description of studies   
Three new studies were identified for inclusion 
in the current update of this review: Comella 
2005; Pappert 2008; Tintner 2005. None of 
these were included in previous versions of this 
review. 
Results of the search   
See: Figure 1, flow diagram of study selection. 
The search strategy returned 1667 records (436 
though MEDLINE; 1042 through EMBASE; 
189 through CENTRAL), resulting in 1450 
records after removing all duplicates. After title 
and abstract screening, 3 articles were assessed 
for full-text screening, with all 3 being included 
for both the qualitative and quantitative 
syntheses. No unpublished trials were retrieved. 
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Included studies   
See Characteristics of included studies. 
The three studies included in this review are 
parallel-group RCTs comparing BtA and BtB for 
adults (aged above 18 years old) with cervical 
dystonia. Trial size varied from 20 to 139 
participants. Two of the included RCT were 
multi-centre studies conducted in the North 
America and Europe (Comella 2005; Pappert 
2008), while the remaining trial was a single-
centred and conducted in the United States 
(Tintner 2005). All trials were conducted in the 
2000's. 
270 participants were enrolled overall, 171 of 
whom were female (63.3%). 141 of the 
participants included in this review were 
randomised to the BtA arm of their respective 
studies, with the remaining 129 participants 
randomised to the BtB arm. The average age of 
participants among the three trials was 53.3 
years. The baseline mean cervical dystonia 
symptoms were moderate to severe in all 
participants, and well matched between study 
Figure 1 Flow diagram of study selection 
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arms, with baseline TWSTRS total scores of 41.8 
and 45.6 for participants in Comella 2005 and 
Pappert 2008, respectively. Tintner 2005 did not 
provide data for baseline TWSTRS total score. 
The mean duration of cervical dystonia was 7.9 
years and 6.6 years for participants in Comella 
2005 and Pappert 2008, respectively. Tintner 
2005 did not provide data for the number of 
years since dystonia diagnosis. Pappert 2008 
enrolled exclusively patients without prior 
exposure to any form of botulinum toxin, while 
the remaining studies (Comella 2005; Tintner 
2005) enrolled exclusively patients with a 
positive response to BtA, for a total of 58.9% 
known positive responders to BtA among all 
participants considered in this review. None of 
the included trials described the method of 
patient referral and recruitment prior to study 
enrolment. Overall, within studies and 
considered together, participants were well 
matched between the BtA and BtB arms. 
All studies were designed to evaluate only a 
single treatment session. Two studies (Comella 
2005; Pappert 2008) used doses from 100 to 
250U of BtA and 5000 to 10000U of BtB, while 
the remaining study (Tintner 2005) refers only to 
botulinum doses being administered at a 1:50 
ratio of BtA to BtB. Techniques and schema of 
botulinum toxin administration did not vary 
considerably among studies. In all trials, the 
toxin was injected into the involved cervical 
dystonia muscles selected by the investigator, 
with the use of electromyography left at 
discretion of the investigator performing the 
injection. 
Comella 2005 and Pappert 2008 both used 
TWSTRS total score at week 4 post-injection as 
the primary efficacy outcomes. Tintner 2005 was 
designed with the specific objective of 
comparing the autonomic effects of botulinum 
toxin, and thus used several measures of 
autonomic function (which will not be 
considered in this review) and reported only 
TWSTRS sub-scores at baseline and at week 3 
post-injection. Comella 2005 and Pappert 2008 
also studied subjective response as assessed by 
patients and clinicians. Regarding safety 
outcomes, all studies reported treatment-
associated adverse events. Only one study 
(Pappert 2008) refers to the method of data 
analysis used, referring to using both per-
protocol (PP) and intention-to-treat (ITT) 
analyses, though only reporting the PP analysis, 
saying that there was no difference between PP 
and ITT. 
All trials were short-term, with an observational 
period lasting 16 to 20 weeks post-injection or 
until such time as reinjection was required. 
Excluded studies   
All reports that were entered for full-text 
screening were assessed as eligible for inclusion 
in this review. 
Risk of bias in included studies   
See Characteristics of included studies: 'Risk of 
Bias' table. 
The included studies were evaluated using a 
modified version of the Cochrane risk of bias 
tool. See Figure 2 and Figure 3 for the risk of 
bias summary graphs. These assessments were 
based on the information available in the 
primary report data. 
None of the included studies were considered to 
have a high risk of bias in all domains, though 
the "independent funding" domain was 
considered to have a high risk of bias in all 
studies, and the "selective reporting" domain 
was considered to have a high risk of bias in one 
study (Tintner 2005). All studies were 
additionally considered to have a low risk of bias 




   Figure 2 Risk of bias graph 1 
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Allocation (selection bias)   
Two studies (Comella 2005; Pappert 2008) 
adequately described the methods of allocation 
(permuted block allocation scheme and 
Interactive Voice Response system, 
respectively), and so were rated as having a low 
risk of bias. The remaining study (Tintner 2005) 
was rated as having an unclear risk of bias. 
Blinding (performance bias and 
detection bias)   
Two studies (Comella 2005; Pappert 2008) 
adequately reported the methods of guaranteeing 
blinding, being correctly executed double-blind 
controlled trials, and so were rated as having a 
low risk of bias. The remaining study (Tintner 
2005) was rated as having an unclear risk of bias. 
Incomplete outcome data (attrition 
bias)   
All studies (Comella 2005; Pappert 2008; Tintner 
2005) adequately reported the number and 
reasons for exclusions in both treatment arms, 
being furthermore evenly distributed across both 
treatment arms, and so were rated as having a 
low risk of bias. 
Selective reporting (reporting bias)   
Two studies (Comella 2005; Pappert 2008) 
adequately reported the number and reasons for 
exclusions in both treatment arms, being 
furthermore evenly distributed across both 
treatment arms, and so were rated as having a 
low risk of bias. The remaining study (Tintner 
2005) was rated as having a high risk of bias. 
This is because it refers, in the method section, 
to having had selected several outcomes, though 
only two of these are reported in the results. 
Moreover, due to inherent BtA properties the 
outcome assessment usually last at least until the 
week 16 after the treatment session, which was 
not accomplished in this study. 
Other potential sources of bias   
Enriched Population 
All included studies potentially had a form of 
enriched population. Two studies (Comella 
2005; Tintner 2005) exclusively enrolled positive 
responders to treatment with BtA, though the 
minimal required effect in the case of Comella 
2005, 30%, was not considered sufficient to be 
assessed as a high risk of bias, but rather unclear. 
Tintner 2005 refers to the inclusion exclusively 
of participants known to have been responsive 
to BtA in the year prior to enrolling in the study, 
though, likewise, the significance of this is 
unclear as pertains to the effect on comparisons 
to BtB. Two studies (Comella 2005; Pappert 
2008) excluded patients known to have poorer 
responses to treatment with botulinum toxin, 
namely patients with pure anterocollis and 
retrocollis were excluded from both trials. 
Non-independent funding 
All studies (Comella 2005; Pappert 2008; Tintner 
2005) were supported, wholly or in part, by 
pharmaceutical companies (Allergan, Inc and 
Soltice Neurosciences, Inc). 
Publication bias 
We intended to use funnel plots to explore 
publication bias. However, due to the small 
number of included studies, the power of this 




Effects of interventions   
The key results of the main comparison 
outcomes can be found in the ‘Summary of 
findings table 1’. 
Preceding data analysis 
Whenever necessary, appropriate imputation 
methods were used in order to combine the 
reported data into the meta-analysis with other 
studies for which full data were available (see 
Dealing with missing data). Cochrane’s software 
tool was used to calculate SD values from SE 
values presented in Pappert 2008. Sensitivity 
analyses were conducted for every study where 
imputation methods were applied. For Tintner 
2005, with regards to the three TWSTRS sub-
scales (pain, severity and disability), we derived 
values for the standard deviation of the change 
from baseline values from a pooled SD formula. 
Primary outcomes 
1. Overall improvement on any 
validated symptomatic rating scale for 
cervical dystonia 
The Toronto Western Spasmodic Torticollis 
Rating Scale (Consky 1994) is currently the most 
common clinical validated tool to assess and 
document the status of patients with cervical 
dystonia. The TWSTRS (total score range, 0 to 
85) is composite of three sub-scales that evaluate 
different features of CD, namely severity (range, 
0 to 35), disability (range, 0 to 30) and pain 
(range, 0 to 20). The higher the score, the greater 
the level of morbidity. In the absence of a 
validated value for a clinically meaningful change 
in TWSTRS total score, we have considered a 
10% change from patients' baseline status as a 
clinically meaningful change. 
Two studies (n=231)(Comella 2005; Pappert 
2008) reported data for the mean change from 
baseline in TWSTRS total score, with no 
difference between the BtA and BtB treatment 
groups, mean difference (MD) -1.44 (95% CI: -
3.58 to 0.70; I2=0%)(Analysis 1.1). 
We were able to use data from all three included 
studies to calculate the improvement on 
TWSTRS sub-scales, with there being no 
difference between the BtA and BtB groups 
with regards to both TWSTRS severity (MD: -
0.31; 95% CI: -1.27 to 0.65) and TWSTRS 
disability (MD: -0.22; 95% CI: -1.21 to 
0.76)(Analysis 1.2; Analysis 1.3). 
2. Proportion of patients with adverse 
events 
One study (n=111)(Pappert 2008) reported data 
concerning the proportion of participants with 
adverse events. In this study BtA and BtB 
treatment were not associated with different 
risks for adverse events, (risk ratio (RR) of 0.72; 
95% CI: 0.51 to 1.00). 
Secondary outcomes 
1. Change in subjective evaluation of 
clinical status evaluated both by patients 
and clinicians 
One study (138 participants)(Comella 2005) 
reported data with regards to subjective 
assessments by both clinicians and patients at 
Figure 3 Risk of bias graph 2 
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week 4 after treatment. The instruments used to 
measure this outcome were the Patient Global 
Assessment (PGA) and Subjective Global 
Assessment (SGA) scales. The PGA and SGA 
ratings ranged from 4 (marked worsening of CD 
signs) to 4 (complete abolishment of CD signs). 
Both forms of subjective assessment, measured 
as mean change from baseline in PGA and SGA, 
did not find a difference between the BtA and 
BtB groups, (PGA MD: 0.20; 95% CI: -0.17 to 
0.57; SGA MD: 0.17; 95% CI: -0.17 to 0.50). 
Pappert 2008 also refers to have studied 
subjective evaluation of clinical status by both 
patients and clinicians, though the final report 
does not include any data regarding this analysis, 
referring only to the fact that all evaluations 
were similar between treatment arms. 
2. Changes in pain scores, as assessed 
with validated assessment tools 
All of the included trials provided data in the 
form of mean change from baseline on 
TWSTRS pain sub-scores (range: 0 to 20), and 
reported an improvement in participants treated 
with BtB compared to BtA with a MD of -0.99 
(95% CI: -1.85 to -0.12; I2=0%)(Analysis 1.7). 
3. Changes in quality of life assessments 
None of the included trials studied the effect of 
BtA or BtB on the quality of life of patients with 
cervical dystonia. 
4. Proportion of participants with specific 
adverse events 
The most frequently reported adverse events 
were dysphagia (n=269)(Comella 2005; Pappert 
2008; Tintner 2005) with a RR of 0.49, favouring 
the BtA group (95% CI: 0.32 to 0.75, I2=27%) 
and sore throat/ dry mouth (n=249)(Comella 
2005; Pappert 2008), with a RR of 0.42 
favouring the BtA group (95% CI: 0.31 to 0.57, 
I2=77%) (Analysis 1.8; Analysis 1.9, respectively) 
For all the other adverse events no statistically 
significant difference was found. The most 
frequent adverse event that was equally present 
in both treatment groups was local pain. 
5. Duration of effect, or number of days 
until need for reinjection or effect 
waning 
This item was reported in two studies 
(n=231)(Comella 2005; Pappert 2008), though 
the data were not eligible for quantitative 
synthesis (meta-analysis) due to this outcome 
being reported as survival time for the median of 
each arm (Michiels 2005). 
Pappert 2008 reported that among its 93 
participants both formulations of botulinum 
toxin did not differ from one another - median 
treatment duration of effect was 13.1 weeks in 
the BtA arm and 13.7 weeks in the BtB arm 
(hazard ratio (HR): 0.95; 95% CI: 0.56 to 1.59; 
log rank p=0.833). A subgroup analysis for 
participants who showed a change at week 4 
(n=83) was also conducted, without a difference 
between the groups (HR: 0.79; 95% CI: 0.45 to 
1.41; log rank p=0.414). 
Comella 2005 reported that among its 138 
participants both formulations of botulinum 
toxin did not differ from one another - median 
treatment duration of effect was 13.0 weeks in 
the BtA arm and 11.7 weeks in the BtB arm 
(95% CI: 0.55 to 1.07). A subgroup analysis for 
participants who showed a change at week 4 was 
conducted, and the difference in median time to 
loss of benefit was 14 weeks for BtA and 12.1 
weeks for BtB. Having run a log rank statistic, 
these two distributions were shown to differ 
(95% CI: 0.43 to 0.98). 
Discussion   
Summary of main results   
This updated review included three randomised, 
parallel-designed, placebo-controlled trials, 
enrolling 270 patients with cervical dystonia, of 
whom 62.3% had been previously treated with 
BtA. BtA and BtB were equally effective in 
reducing overall disease impairment, including 
disease severity and disability, though patients 
treated with BtB benefited from greater 
reductions in disease-associated pain. Subjective 
assessments by both patients and clinicians were 
likewise equivalent between BtA and BtB. The 
comparative impacts of both forms of 
botulinum toxin on other domains of 
participants’ quality of life, such as social 
functioning or mental health, have not been 
addressed in included trials. 
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Overall adverse event rates were not different 
between groups. However, the short duration of 
the trials, as well as the reduced sample size 
precludes strong conclusions with regards to the 
lack of differences between BtB and placebo. 
The most common adverse events that were 
different between the BtA and BtB groups were 
dysphagia and sore throat/dry mouth, both 
considered related to treatment and being 
between 2 and 3 times more frequent among 
BtB-treated patients, with an NNTH of 12 and 
6, respectively. No fatalities or serious adverse 
events were considered related to either 
treatment in any of the trials. Data for special 
subpopulations, as children and pregnant 
women, was not available. 
Low to moderate statistical heterogeneity was 
found for most efficacy and safety (except for 
sore throat/dry mouth) outcome estimates. 
Overall completeness and 
applicability of evidence   
All included trials addressed the primary 
research question directly, using the same 
assessment tool (TWSTRS). However, data was 
not fully reported for all outcomes, and in some 
cases results could not be pooled and compared 
across studies. This limits the amount of data 
available and, consequently, the confidence in 
overall conclusions. 
Four noteworthy factors challenge the 
implementation of the evidence in this review. 
First, there was a limited and considerably 
heterogeneous regional distribution, with all 
trials being conducted in Europe or North 
America. Differences in clinical practice, training 
of experts, and local guidelines in other regions 
of the world may conceivably present an 
obstacle to application of the evidence here 
demonstrated. Second, the total number of 
participants across all outcomes was less than 
the number of participants that is calculated by a 
standard sample size calculation for a single 
adequately powered study. More studies are 
needed to provide robust backing for the 
evidence presented. Third, it is frequent for 
patients to have concomitant medications for 
their condition, such as muscle relaxants and 
benzodiazepines. In trials, such medications are 
reasonably required to be on a stable dose for 
many weeks to avoid confounding factors. As a 
result, little is currently known about the impact 
of these drug regimens with regards to 
implementation of the evidence in this review. 
Fourth, several outcomes of interest were either 
poorly reported or omitted completely. Namely, 
no quality of life assessments were reported in 
any of the included studies; subjective 
assessments by both patients and clinicians was 
not reported in two of the included studies; and 
the proportion of participants with adverse 
events was also not reported in two of the 
included studies. 
Quality of the evidence   
See Characteristics of included studies, 'Risk of 
bias' tables, and 'Risk of bias' summary tables 
(Figure 2; Figure 3). 
We considered all studies to be at high risk of 
bias due to their being non-independently 
funded. We additionally considered Tintner 2005 
to be at a high risk of reporting bias, since it did 
not report outcomes that were collected, and 
without providing any explanation for this 
option. Tintner 2005 is additionally at an unclear 
risk of bias for all domains with the exception of 
attrition bias. We consider the risk of bias due to 
an enriched population to be unclear in all 
studies. Finally, statistical heterogeneity was low-
to-moderate for all studied outcomes with the 
exception of the proportion of participants with 
sore throat/ dry mouth. 
Some outcomes could not be compared across 
studies, as some studies lack reporting of 
relevant data. Imbalances between baseline 
characteristics of the participants and incomplete 
description of the variables precluded us to 
confidently impute values for missing data, 
further reducing the amount of combinable data, 
and therefore the precision of the results. 
The included trials enrolled between 20 and 139 
participants, and taken as a whole, the the total 
number of participants across all outcomes was 
less than the number of participants that is 
calculated by a standard sample size calculation 
for a single adequately-powered study. Taken 
together, we consider that there is low-to-
moderate quality evidence that a single treatment 
session of BtA and a single treatment session of 
BtB, in certain types of cervical dystonia, are 
equally efficacious in reducing disease 
impairment, including severity and disability, 
with treatment with BtB providing a greater 
reduction in pain. However, the quality of the 
evidence is low and no robust conclusions can 
be made regarding safety and tolerability, as well 
as regarding continued responsiveness and long-
term efficacy, which are important aspects in a 
chronic condition such as cervical dystonia. 
Quality of evidence is, however, moderate in 
relation to the increased risk of dysphagia in 
patients treated with BtB. 
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Potential biases in the review 
process   
Although we followed the methods 
recommended by Cochrane in order to minimize 
bias in the review process, certain areas are 
deserving of attention. Despite having contacted 
experts in the area, not having searched all 
available clinical trial registries opens the current 
review to two potential problems: firstly, 
possibly having missed trials and also the 
possibility of introducing publication bias. 
An additional bias was that we could not obtain 
data for all outcomes in the included trials. A 
further limitation of this review is the small 
number of participants, with each outcome not 
having an adequate sample size for a single 
adequately powered study. Thus, the results of 
the pooled analysis should be thought with 
caution specially in the presence of statistically 
heterogeneity, as further studies may have an 
important impact in effect size estimations. 
Agreements and disagreements 
with other studies or reviews   
The current review is, to our knowledge, the 
first systematic review with data that addresses 
the question of whether one type of botulinum 
toxin is superior to another or not. All the RCTs 
addressing the same question have been 
included in the current review. 
Authors' 
conclusions   
Implications for practice   
In this updated Cochrane review we found that 
a single treatment session of BtA and a single 
treatment session of BtB are equally effective 
and well tolerated in the treatment of adults with 
certain types of cervical dystonia. Treatment 
with BtB causes a greater decrease disease-
associated pain whilst also increasing the rate of 
dysphagia and sore throat/dry mouth when 
compared to treatment with BtA. Overall, there 
is no clinical evidence to support or not support 
the preferential use of one form of botulinum 
toxin over another. No conclusions can be made 
regarding patients with pure retrocollis or 
anterocollis as these were predominantly 
excluded in the clinical trials. 
Implications for research   
We did not have access to the full research data 
produced so far for BtA versus BtB in cervical 
dystonia. Thus, it is difficult to determine which 
and how many resources should be invested in 
future research. 
The net benefit of both a single BtA and BtB 
injection in the treatment of cervical dystonia 
has been established in the published trials. 
Nonetheless, further studies are needed to 
establish the relative effectiveness of different 
doses of BtB, assessing efficacy, safety, duration 
of effect and quality of life across regimes. 
Because therapy typically requires optimising a 
dose for each patient rather than administering 
fixed units of botulinum toxin, such a line of 
research would be important to support the 
physician’s management of doses and allow for a 
more solid and safe individualization of a 
patient’s treatment. 
Future research concerning all formulations of 
botulinum neurotoxin should endeavour to 
establish clinical effectiveness not only based on 
changes from baseline, but preferably based on 
validated measures of Minimal Clinically 
Important Difference/ Change (Brożek 2006). 
Research is required in order to establish such a 
parameter for the TWSTRS, currently the most 
widely used and disseminated clinical scale in the 
field. We are, however, aware of an effort to 
create a new clinical scale in dystonia - the 
Comprehensive Cervical Dystonia Rating Scale 
(Comella 2015), which will include a revision of 
the TWSTRS, to be named TWSTRS-2, with a 
Minimal Clinically Important Change validation 
being planned. 
It is currently uncertain whether or not the 
clinical effectiveness of botulinum toxin decays 
over time, with repeated treatment sessions, 
and/or whether a possible lost of effectiveness 
occur in all clinical domains. Another related 
aspect is the possible development of BtB-non-
responsiveness, as there is no plausible 
theoretical reason as to why this would not 
occur. Future studies comparing BtA and BtB 
should address the comparative proportion of 
patients who develop non-responsiveness to 
treatment. 
Finally, in conducting this systematic review we 
were faced with the fact that there is no defined 
Core Outcome Set in cervical dystonia research, 
as there is in other areas (Tugwell 2007). The 
definition of a set of core outcome measures to 
be included in future research, via well-
established methodology to determine the 
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inclusion of patient-reported outcomes 
(Macefield 2014) would be relevant to promote 
research in this field, as well as to support the 
clinical effectiveness of BtB. 
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Differences 
between protocol 
and review   
For this updated review the study designs 
accepted were restricted to parallel-group. No 
changes were made in the type of participants 
included or in the interventions allowed. 
Adverse events, which were originally a 
secondary outcome, were included in this 
updated review as a primary safety outcome. In 
this safety analysis we considered also the 
proportion of participants with the most 
frequent adverse events, not stated in the 
original protocol. An assessment of the duration 
of effect was included as a new secondary 
outcome measure. 
The search strategy was prolonged from the 
inception to October 2015. 
New approaches were assumed to deal with 
missing data and unit of analysis issue. 
The latest recommended Cochrane tool for 
assessing risk of bias was used in this review, 
which was expanded to include two additional 
criteria, added by the review authors. Blinding of 
outcome assessment was analysed in two new 
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subcategories: subjective and objective 
assessment. 











Characteristics of  studies   
Characteristics of included studies   
 
Comella 2005 
Methods Randomised, double-blind, controlled study. Randomisation in permuted block 
allocation schemes. 
Data was collected at baseline, week 4, and subsequently every 2 weeks up to 20 
weeks post-injection. 
Data analysed on a ITT basis. 
Participants The study was conducted in the outpatient offices of unspecified dystonia study 
centres. 
Mean age of participants was 56.7 years; 68% were female; the combined 
duration of cervical dystonia of 7.9 years. The mean TWSTRS total score was 
41.8. 
All participants had previously been exposed to a form of botulinum 
neurotoxin, and were required to have moderate severity CD, as well as a 
minimum of 15 on the TWSTRS motor severity subsection, for inclusion. 
Predominant anterocollis and retrocollis were exclusionary criteria. 
There was a total of 139 randomised participants. 
Interventions Participants were randomised into two groups, the Botox group, containing 74 
participants, and the MyoBloc group, containing 65 participants. 
Botox was commercially obtained in vials containing 100 U Clostridium 
botulinum toxin type A, 0.5 mg albumin (human), and 0.9 mg sodium chloride 
in a sterile in a vacuum-dried form without a preservative. BoNTA was stored 
at a temperature at or below -5°C and reconstituted within 4 hours of 
administration with 1 mL of 0.9% sterile unpreserved saline to provide a final 
concentration of 100 U/mL. Subjects randomised to Botox received a maximal 
dose of 250 U (2.5 mL). Subjects were injected with a volume of the 
appropriate study drug based on previous injection amounts. Muscle selection, 
dosing into each muscle, number of injection sites, and use of 
electromyography were at the discretion of the injecting physician. 
MyoBloc was obtained in vials containing at least 5000 U Clostridium 
botulinum toxin type B, 0.05% albumin (human), 0.01 M sodium succinate, and 
0.1 M sodium chloride buffer at a pH of 5.6. Commercially available vials of 
MyoBloc contain overfill of approximately 0.1 to 0.2 mL or 500 to 1,000 U 
MyoBloc. MyoBloc was stored at a temperature between 2° and 8°C. Each vial 
of MyoBloc was diluted with 0.25 mL of 0.9% sterile unpreserved saline to 
provide a concentration of at least 4000 U/mL. Subjects randomized to 
MyoBloc received a maximal dose of 10000 U (2.5 mL). 
Outcomes The primary outcome measures were the change in total TWSTRS score at 
week 4, the duration of clinical effect (the time in days until the target 
TWSTRS score was reached), and adverse effects evaluated by spontaneous 
report and adverse events interviews. 
The secondary outcomes measured were the Physician Global Assessment of 
Change (-4 is very marked worsening, 0 is no change and +4 is complete 
remission), Patient Global Assessment and pain and discomfort at 
baseline injection. 













Low risk “Random assignments were generated by the study 
biostatistician, were stratified by center, and used permuted 
block allocation schemes with blocks of randomly allocated 
lengths of two or four. The study biostatistician ensured 
that the initial assignments were balanced across centers. 
The permuted block approach prevented imbalances in the 
numbers randomized to each treatment arm..” 
Allocation concealment 
(selection bias) 
Low risk “Random assignments were generated by the study 
biostatistician, were stratified by center, and used permuted 
block allocation schemes with blocks of randomly allocated 
lengths of two or four. The study biostatistician ensured 
that the initial assignments were balanced across centers. 
The permuted block approach prevented imbalances in the 
numbers randomized to each treatment arm..” 






Low risk “The principal/treating investigator (PI) en- rolled the 
subjects, assessed the inclusion and exclusion criteria, 
obtained informed consent, applied and evaluated the 
UBI (Unilateral Brow Injection), 
performed the injection of study drug (BoNTA or 
BoNTB), reported complications associated with injection, 
assessed adverse events, and determined when subjects 
reached the defined end point of the study. (…) The PI, RI, 
and coordinator were blinded to serotype administered to 
each subject.” 
Blinding of participants 
and personnel 
(performance bias) 
Outcome group: Rating 
Investigator (RI) 
Low risk “The rating investigator (RI) reviewed the TWSTRS 
teaching tape to ensure uniform ratings and assessed 
subjects using the TWSTRS (motor severity, disability, and 
pain) and the physician’s global assessment (PGA). The RI 
did not perform other study procedures. (…) The PI, RI, 
and coordinator were blinded to serotype administered to 
each subject.” 
Blinding of participants 
and personnel 
(performance bias) 
Outcome group: Study 
Coordinator 
Low risk “The study coordinator scheduled study visits, recorded 
concomitant medications, obtained the subjective global 
assessment (SGA), and completed study-related 
questionnaires. (…) The PI, RI, and coordinator were 
blinded to serotype administered to each subject.” 







“The drug preparer obtained the randomization code for 
each subject from the study biostatistician and prepared the 
BoNTA or BoNTB.” 
The drug preparer was not involved in other study 
procedures. 






“The PI, RI, and coordinator were blinded to serotype 
administered to each subject.” 






BtA, which could have led to the recognition of the 
expected effect, or to the lack of it. However, this would 
presumably not have an effect as the comparison arm was 
also a botulinum toxin formulation. 
Incomplete outcome 
data (attrition bias) 
Low risk Only one post-randomisation withdrawal occurred, in the 
BTA group (inability to travel to the study site). 
The ITT analysis of the primary outcome variables for the 
TWSTRS and adverse events was done for all participants 
examined at week 4. 
Selective reporting 
(reporting bias) 
Low risk The expected outcomes that are usually evaluated in 
intervention trials for this condition were reported in this 
study. 
Enriched population - 
exclusive enrolment of 
positive responders 
Unclear risk “All subjects were followed up in outpatient clinics and had 
previous successful treatment with BoNTA, with a 
subjective report of at least 30% benefit.” 
“At the baseline visit, the PI evaluated the UBI (Unilateral 
Brow Injection) and excluded subjects with UBI indicating 
clinical resistance (no effacement of brow wrinkling). 
Subjects were then randomized to either BoNTA or 
BoNTB” 
Enriched population - 
exclusion of poor 
responders 
Unclear risk 
“Subjects were also excluded if they had predominant 
anterocollis or retrocollis” 
Independent Funding High risk “Supported primarily by an unrestricted research grant 
from Allergan Inc., Irvine, CA.” 
 
Pappert 2008 
Methods Randomised, double-blind, controlled trial. Randomisation was done via a 
Interactive Voice Response system, which created a subject randomisation 
number which was then forwarded to the site pharmacist who prepared the 
study drug. 
Data was collected at baseline, week 4 post-injection and every 4 weeks until 
there was a further need for botulinum therapy. 
Both Per Protocol and Intention To Treat analyses were performed but the 
study reports only the PP analysis. 
Participants This multi-centre trial was conducted in 24 sites in Europe (Poland, Hungary, 
UK, Italy, Spain, Germany, Slovakia, France and Portugal). 
Mean age of participants was 48.9 years; 55.9% were female; and the average 
duration of Cervical Dystonia was 6.6 years. 
Pure anterocollis and retrocollis, as well as previous treatment with botulinum 
toxin were exclusionary criteria. 
There was a total of 111 randomised participants. 
Interventions Pateints were randomised into two groups, the BoNT-A group, with 56 
participants, and the BoNT-B, containing 55 participants. 
BoNT-A (BOTOX) was commercially obtained by the pharmacy (100 U of 
vacuum-dried BoNT-A neurotoxin complex) and stored at or below _5°C). An 
unblended pharmacist prepared the study drug by reconstituting two vials of 
BoNT-A with sterile unpreserved saline (1.3 mL/vial). The pharmacist drew up 
1 mL of solution (BoNT-A) from each vial into two syringes (1 mL/syringe). 
The final concentration of BoNT-A was 150 U/2 mL. Electromyography was 
used at the discretion of the investigator providing the injection. 
BoNT-B (MYOBLOCR/NEUROBLOCR) was supplied by the manufacturer 
in insulated shipping boxes, and maintained at 2 to 8°C. BoNT-B is a clear, 
colorless to light yellow, sterile injectable solution containing 5,000 units (U) of 
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BoNT-B per mL (10,000 U/2 mL) in an isotonic solution of 0.05% human 
serum albumin/0.01M succinate/0.1M sodium chloride buffer at an 
approximate pH of 5.6. An unblinded pharmacist prepared two syringes with 1 
mL of BoNT-B (5,000 U/mL) in each syringe. The final concentration of 
BoNT-B was 10,000 U/2 mL. Electromyography was used at the discretion of 
the investigator providing the injection. 
Outcomes The primary outcome measure of the study was change in total 
TWSTRS score at 4 weeks post-injection. 
The secondary outcome measures were change in TWSTRS subscores (ie, 
Pain, Severity and Disability), Subject Pain Assessment on Visual Analogue 
Scale, Primary Investigator and Patient Global Assessment (5-points scale 
for both frequency and intensity) on Visual Analogue Scale at week 4, 
and adverse events by spontaneous reporting and on investigation. 












Low risk “Subjects were randomized in a 1:1 ratio of BoNT-A to 
BoNT-B. The site Principal Investigator (PI) contacted an 




Low risk “Treatment allocation for the randomization number was 
forwarded to the site pharmacist who prepared the study 
drug and had no contact with the subject or injector. All 
other study personnel were blinded.” 






Low risk “At screening (≤21 days prior to baseline visit), the PI 
performed a history, examination, and confirmed 
inclusion/exclusion criteria. At baseline, prior to injection, 
the PI performed the TWSTRS (…). At week 4 and all 
subsequent visits, the PI performed the TWSTRS and 
Investigator Global VAS [0 mm (much worse) to 100 mm 
(much better) at the time of evaluation compared to 
baseline].” 
“All other study personnel were blinded” 
Blinding of participants 
and personnel 
(performance bias) 
Outcome group: Rating 
Investigator (RI) 
Low risk “At baseline, prior to injection, (…) the AI administered the 
subject Pain Visual Analogue Scale (VAS) [0 mm (worst 
pain ever) to 100 mm (no pain)]. 
The Administrative Investigator conducted the remaining 
visits including collection of AEs and the administration of 
the Subject Pain VAS and Subject Global VAS [ranging 
from 0 mm (much worse) to 100 mm (much better) at the 
time of evaluation compared to baseline].” 
“All other study personnel were blinded” 
Blinding of participants 
and personnel 
(performance bias) 
Outcome group: Study 
Coordinator 
Low risk “At baseline, prior to injection, (…) the AI administered the 
subject Pain Visual Analogue Scale (VAS) [0 mm (worst 
pain ever) to 100 mm (no pain)]. 
The Administrative Investigator conducted the remaining 
visits including collection of AEs and the administration of 
the Subject Pain VAS and Subject Global VAS [ranging 
from 0 mm (much worse) to 100 mm (much better) at the 
time of evaluation compared to baseline].” 
“All other study personnel were blinded” 
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“An unblinded pharmacist prepared the study drug”. 
“pharmacist who prepared the study drug and had no 
contact with the subject or injector”. 






“All other study personnel were blinded.” 






All participants were toxin-naïve. However, this would 
presumably not have an effect as the comparison arm was 
also a botulinum toxin formulation. 
Incomplete outcome 
data (attrition bias) 
Low risk Post-randomisation exclusions were low and roughly 
distributed evenly between groups (‘BoNT-A’ group=8; 
‘BoNT-B’ group=10). 
The reasons for exclusion were presented. Five of the 
exclusions in the ‘BoNT-B’ group, and all of them (8) in the 
‘BoNT-A’ group, were due to “Protocol Violations”, which 
were not specified. However, the authors describe that “all 
13 subjects that were excluded for protocol violations in the 
PPP were from one site where the study personnel had not 
been appropriately trained.” 
Selective reporting 
(reporting bias) 
Low risk The expected outcomes that are usually evaluated in 
intervention trials for this condition were reported in this 
study. 
Enriched population - 
exclusive enrolment of 
positive responders 
Low risk 
“Exclusion criteria included: (…) previous treatment with 
BoNT” 
Enriched population - 
exclusion of poor 
responders 
Unclear risk 
“Exclusion criteria included: pure antero- or retrocollis” 
Independent Funding High risk “Eric J. Pappert, MD and Terry Germanson, PhD for The 
Myobloc/Neurobloc European Cervical Dystonia Study 
Group” 
“The first named author (EJP) is an employee of Solstice 
Neurosciences, Inc. maker of MYOBLOC® (BoNT-B) and 
took charge of the publication and analysis after the study 
was completed. (…) The statistical consultant (TG) is an 
independent contractor paid for her analytic time by Solstice 
Neurosciences, Inc. and has nothing further to disclose.” 
 
Tintner 2005 
Methods Randomised, double-blind, controlled trial. Randomisation method not 
explained. 
Data was collected at baseline and at week 2 post-injection. 
It is unclear wether the data was analysed per protocol or by an intention-to-
treat method. 
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Participants The location in which the study was conducted is not mentioned. 
Mean ages were 55 for the BTX-A group and 64 for the BTX-B group. 14 of 
the 20 participants were female. The duration of diseases of the participants is 
unknown. 
Participants were required to have a previous response to BTX-A within the 
last year of sufficient magnitude for functional improvement. 
There was a total of 20 randomised participants. 
Interventions There were 11 participants allocated to the BTX-A group and 9 to the BTX-B 
group. 
No information was provided in relation to the name of the drugs, the dose or 
frequency of administration of BTX therapy. No information about follow-up 
time was provided. 
Outcomes The primary outcomes in this study were the TWSTRS sub-score at week 2 
post-injection. 
Secondary outcomes were heart rate, blood pressure, orthostatic heart rate 
regulation, heart rate variation with respiration,saliva production, ocular 
autonomic testing, the Composite Autonomic Scoring Scale, and 








Support for judgement 
Random sequence 
generation (selection bias) 
Unclear risk The text refers to this trial being randomized, though 




Method of allocation concealment not specified. 




Principal Investigator (PI) 
Unclear risk 
The text refers to this trial being double-blind, though no 
evidence of adequate participant blinding is made. 
Blinding of participants 
and personnel 
(performance bias) 
Outcome group: Rating 
Investigator (RI) 
Unclear risk 
The text refers to this trial being double-blind, though no 
evidence of adequate participant blinding is made. 
Blinding of participants 
and personnel 
(performance bias) 
Outcome group: Study 
Coordinator 
Unclear risk 
The text refers to this trial being double-blind, though no 
evidence of adequate participant blinding is made. 







The text refers to this trial being double-blind, though no 
evidence of adequate participant blinding is made. 
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The text refers to this trial being double-blind, though no 
evidence of adequate investigator blinding is made. 






The text refers to this trial being double-blind, though no 
evidence of adequate investigator blinding is made. 
Incomplete outcome data 
(attrition bias) 
Low risk “20 subjects with cervical dystonia responsive to BTX-A 
were randomized and completed the study” 
Selective reporting 
(reporting bias) 
High risk Although the report refers, in the method section, to 
having had selected several outcomes, only two of these 
are reported in the results. Moreover, due to inherent 
BtA proprieties the outcome assessment usually last at 
least until the week 16 after the treatment section, which 
was not accomplished in this study. 
Enriched population - 
exclusive enrolment of 
positive responders 
Unclear risk 
Subjects were required to be known responders to the 
effects of BTA within the past year. 
Enriched population - 
exclusion of poor 
responders 
Low risk 
No reference made to exclusion of poor responders 
Independent Funding High risk Refers to this study having been supported by a grant 
from Allergan Inc. 
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Data and analyses 
Botulinum toxin type A versus Botulinum toxin type B 
 
Outcome or Subgroup Studies Participants Statistical Method 
Effect 
Estimate 
1.1 Overall Cervical 
Dystonia improvement as 
assessed with validated 
scales: change from 
baseline to week 4 
2 231 Mean Difference (IV, 
Fixed, 95% CI) 
-1.44 [-3.58, 
0.70] 
1.2 Cervical Dystonia 
associated Severity: 
change from baseline to 
week 2-4 as assessed with 
validated scales 
3  Mean Difference (IV, 
Fixed, 95% CI) 
-0.31 [-1.27, 
0.65] 
1.3 Cervical Dystonia 
associated Disability: 
change from baseline to 
week 2-4 as assessed with 
validated scales 
3  Mean Difference (IV, 
Fixed, 95% CI) 
-0.22 [-1.21, 
0.76] 
1.4 Proportion of 
patients with adverse 
events 
1 111 Risk Ratio (M-H, Fixed, 
95% CI) 
0.72 [0.51, 1.00] 
1.5 Subjective change as 
assessed by the patient at 
week 4 
1 138 Mean Difference (IV, 
Random, 95% CI) 
0.20 [-0.17, 0.57] 
1.6 Subjective change as 
assessed by clinician at 
week 4 
1 138 Std. Mean Difference 
(IV, Random, 95% CI) 
0.17 [-0.17, 0.50] 
1.7 Cervical Dystonia 
associated Pain: change 
from baseline to week 2-4 
as assessed with validated 
scales 
3  Mean Difference (IV, 
Fixed, 95% CI) 
-0.99 [-1.85, -
0.12] 
1.8 Dysphagia 3 269 Risk Ratio (M-H, Fixed, 
95% CI) 
0.49 [0.32, 0.75] 
1.9 Sore Throat/Dry 
Mouth 
2 249 Risk Ratio (M-H, Fixed, 
95% CI) 
0.42 [0.31, 0.57] 
1.10 Local Pain (Injection 
Site) 











Figure 4 Analysis 1.1 
Figure 6 Analysis 1.2 







Figure 7 Analysis 1.7 
Figure 9 Analysis 1.8 




Sources of  support 
 
Internal sources 
 Cochrane Movement Disorders Group, Portugal 
 The Walton Centre for Neurology and Neurosurgery, UK 
External sources 




1 MEDLINE search strategy 
#1 randomized controlled trial.pt. 
#2 controlled clinical trial.pt. 
#3 randomized.ab. 
#4 placebo.ab. 
#5 clinical trials as topic.sh. 
#6 randomly.ab. 
#7 trial.ti. 
#8 1 or 2 or 3 or 4 or 5 or 6 or 7 
#9 exp animals/ not humans.sh. 
#10 ((randomized controlled trial or controlled clinical trial or randomized or 
placebo or clinical trials as topic or 
randomly or trial) not (animals not humans)).af,pt. 
#11 exp botulinum toxins/ 
#12 exp botulinum toxins, type A/ 
#13 (botul$ adj2 tox$).ti,ab. 
 42 
#14 (botox or dysport or xeomin or myobloc or rimabotulinum$ or abobotuli$ 
or onabotulinum$ or oculinum or 
purtox or CNBTX or Neuronox).ti,ab. 
#15 11 or 12 or 13 or 14 
#16 exp animals/ not humans/ 
#17 ((botulinum toxins or botulinum toxins, type A or (botul$ adj2 tox$) or 
(botox or dysport or xeomin or 
myobloc or rimabotulinum$ or abobotuli$ or onabotulinum$ or oculinum or 
purtox or CNBTX or Neuronox)) not 
(animals not humans)).af. 
#18 (cervic$ adj2 dysto$).ti,ab. 
#19 blepharosp$.ti,ab. 
#20 (hem$ adj2 spasm$).ti,ab. 
#21 (meige and (dysto$ or syndrom$)).ti,ab. 
#22 (crani$ adj2 dysto$).ti,ab. 
#23 (foca$ adj2 dysto$).ti,ab. 
#24 (write$ and (cramp$ or dysto$)).ti,ab. 
#25 torticol$.ti,ab. 
#26 exp dystonic disorders/ 
#27 exp dystonia/ 
#28 exp torticollis/ 
#29 exp blepharospasm/ 
#30 exp meige syndrome/ 
#31 exp hemifacial spasm/ 
#32 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 
or 31 
#33 exp animals/ not humans/ 
#34 (((cervic$ adj2 dysto$) or blepharosp$ or (hem$ adj2 spasm$) or (meige 
and (dysto$ or syndrom$)) or 
(crani$ adj2 dysto$) or (foca$ adj2 dysto$) or (write$ and (cramp$ or dysto$)) 
or torticol$ or dystonic disorders or 
dystonia or torticollis or blepharospasm or meige syndrome or hemifacial 
spasm) not (animals not humans)).af. 
#35 10 and 17 and 34 
 
 43 
2 EMBASE search strategy 
#1 random$.tw. 
#2 clinical trial:.mp. 
#3 placebo$.mp. 
#4 double-blind$.tw. 
#5 1 or 2 or 3 or 4 
#6 5 
#7 limit 6 to human 
#8 (cervic$ adj2 dysto$).ti,ab. 
#9 blepharosp$.ti,ab. 
#10 (hem$ adj2 spasm$).ti,ab. 
#11 (meige and (dysto$ or syndrom$)).ti,ab. 
#12 (crani$ adj2 dysto$).ti,ab. 
#13 (foca$ adj2 dysto$).ti,ab. 
#14 (write$ and (cramp$ or dysto$)).ti,ab. 
#15 torticol$.ti,ab. 
#16 exp Dystonic Disorders/ 
#17 exp Dystonia/ 
#18 exp torticollis/ 
#19 exp blepharospasm/ 
#20 exp Meige Syndrome/ 
#21 exp Hemifacial Spasm/ 
#22 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 
21 
#23 22 
#24 limit 23 to human 
#25 (botul$ adj2 tox$).ti,ab. 
#26 (botox or dysport or xeomin or myobloc or rimabotulinum$ or abobotuli$ 
or onabotulinum$ or oculinum or 
purtox or CNBTX or Neuronox).ti,ab. 
#27 exp Botulinum Toxins/ 
#28 exp Botulinum Toxins, Type A/ 
#29 25 or 26 or 27 or 28 
 44 
#30 29 
#31 limit 30 to human 
#32 7 and 24 and 31 
 
3 CENTRAL search strategy 
#1 MeSH descriptor: [Botulinum Toxins] explode all trees 
#2 MeSH descriptor: [Botulinum Toxins, Type A] explode all trees 
#3 (botul* near/2 tox*):ti,ab 
#4 (botox or dysport or xeomin or myobloc or rimabotulinum* or abobotuli* 
or onabotulinum* or oculinum or 
purtox or CNBTX or Neuronox):ti,ab 
#5 {or #1-#4} 
#6 MeSH descriptor: [Animals] explode all trees 
#7 MeSH descriptor: [Humans] explode all trees 
#8#6 not #7 
#9#5 not #8 
#10 (cervic* near/2 dysto*):ti,ab 
#11 blepharosp*:ti,ab 
#12 (hem* near/2 spasm*):ti,ab 
#13 (meige and (dysto* or syndrom*)):ti,ab 
#14 (crani* near/2 dysto*):ti,ab 
#15 (foca* near/2 dysto*):ti,ab 
#16 (write* and (cramp* or dysto*)):ti,ab 
#17 torticol*:ti,ab 
#18 MeSH descriptor: [Dystonic Disorders] explode all trees 
#19 MeSH descriptor: [Dystonia] explode all trees 
#20 MeSH descriptor: [Torticollis] explode all trees 
#21 MeSH descriptor: [Blepharospasm] explode all trees 
#22 MeSH descriptor: [Meige Syndrome] explode all trees 
#23 MeSH descriptor: [Hemifacial Spasm] explode all trees 
#24 {or #10-#23} 
#25 MeSH descriptor: [Animals] explode all trees 
#26 MeSH descriptor: [Humans] explode all trees 
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#27 #25 not #26 
#28 #24 not #27 
 
